Aileron up 35% on advancement of ALRN-6924 + Ibrance study
Seeking Alpha
Published Jan 16, 2019 01:15PM ET
Aileron up 35% on advancement of ALRN-6924 + Ibrance study
- Thinly traded nano cap Aileron Therapeutics (ALRN +35.1%) is up on an 8x surge in volume following its announcement that dosing is underway in an expansion cohort in its Phase 2a clinical trial evaluating lead candidate ALRN-6924, combined with Pfizer 's (PFE -0.6%) IBRANCE (palbociclib), in patients with MDM2-amplified solid tumors.
- The new arm will enroll up to 25 participants. Preliminary data should be available in H2.
- ALRN-6924 is a cell-permeating peptide that mimics the p53 tumor suppressor protein to disrupt its interaction with MDMX and MDM2, two proteins that interfere with its action.
- Palbociclib inhibits two enzymes, CDK4 and CDK6, that play key roles in the cell cycle. Blocking their action interferes with cancer cell proliferation.
- Now read: Amarin: Evaluating The Merits Of A Potential Pfizer Acquisition
Original article
Get The News You Want
Written By: Seeking Alpha
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.